Author

F. Meric-Bernstam

h-index 13 View on Semantic Scholar

We have 3 of 150 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Oct 2026

Sunitinib in Patients With Various Solid Tumors With FGFR1/2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

PURPOSE TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of two cohorts of patients with various solid tumors with FGFR1 or FGFR2 alterations treated with sunitinib are reported. METHODS Eligi...

Gordan Srkalovic, M. Rothe, E. Garrett-Mayer et al. · JCO Precision Oncology · 0 citations

Clinical trial Open access Aug 2026

Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial

A phase 2 clinical trial investigating neoadjuvant zanidatamab (HER2-targeting antibody) in patients with early-stage HER2-positive breast cancer found de-escalation to HER2-targeted therapy alone may be feasible.

V. Valero, P. Pohlmann, J. Mouabbi et al. · Nature Communications · 0 citations

Open access Aug 2026

Proteogenomic profiling identifies FGFR2b as a prevalent cell-surface target in intrahepatic cholangiocarcinoma.

This approach identified a unique peptide corresponding to FGFR2b, a splicing isoform of FGFR2, that demonstrated markedly higher tumor enrichment than the alternative FGFR2 isoform, FGFR2c.

N. Shah, Beatriz Alvarado-Hernandez, Xinyue Chen et al. · Clinical Cancer Research · 0 citations